Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.52 |
| ▸ | FER | P16591 | 1/20 | 0.52 |
| ▸ | LTK | P29376 | 1/20 | 0.52 |
| ▸ | CDK8 | P49336 | 1/20 | 0.52 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.52 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | CTRC | Q99895 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16566263 | 0.96 | LRRK2 (0.52) | LRRK2MAOAMAOBPDGFRAFER | |
| SCHEMBL3005009 | 0.86 | LRRK2 (0.48) | LRRK2MAOAMAOBPDGFRAFER | |
| Isoindigo SCHEMBL9899736 | 0.82 | LRRK2 (0.67) | LRRK2MAOAMAOBPDGFRAFER | |
| Isoindigo SCHEMBL12386233 | 0.82 | LRRK2 (0.67) | LRRK2MAOAMAOBPDGFRAFER | |
| Isoindigo SCHEMBL9899740 | 0.82 | LRRK2 (0.67) | LRRK2MAOAMAOBPDGFRAFER | |
| Isoindigo SCHEMBL29349649 | 0.82 | LRRK2 (0.67) | LRRK2MAOAMAOBPDGFRAFER | |
| SCHEMBL13243415 | 0.82 | SETD7 (0.57) | LRRK2MAOAMAOBPDGFRAFER | |
| SCHEMBL4679160 | 0.78 | NTRK1 (0.44) | LRRK2MAOAMAOBPDGFRAFER | |
| SCHEMBL10814662 | 0.77 | LRRK2 (0.43) | LRRK2MAOAMAOBPDGFRAFER | |
| SCHEMBL6636725 | 0.76 | LRRK2 (0.46) | LRRK2MAOAMAOBPDGFRAFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200032353-A1 | DETECTION OF MET AMPLIFICATION TO PREDICT RESPONSIVENESS OF CANCER TO DRUGS | THE GENERAL HOSPITAL CORPORATION (US) | 2020-01-30 | — | — | US | disclosed |
| US-20150330967-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING PANCREATIC CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2015-11-19 | — | — | US | disclosed |
| US-20140162277-A1 | METHOD FOR PREDICTING RESPONSIVENESS TO DRUGS | THE GENERAL HOSPITAL CORPORATION (US) | 2014-06-12 | — | — | US | disclosed |
| US-8652786-B2 | Method for predicting responsiveness to drugs | THE GENERAL HOSPITAL CORPORATION (US) | 2014-02-18 | — | — | US | disclosed |
| US-20110092452-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING PANCREATIC CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-04-21 | — | — | US | disclosed |
| WO-2009111644-A2 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING PANCREATIC CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20080220424-A1 | Method for Predicting Responsiveness to Drugs | THE GENERAL HOSPITAL CORPORATION (US) | 2008-09-11 | — | — | US | disclosed |
| US-20060246492-A1 | Method for predicting responsiveness to drugs | THE GENERAL HOSPITAL CORPORATION (US) | 2006-11-02 | — | — | US | disclosed |
| WO-2006108048-A1 | METHOD FOR PREDICTING RESPONSIVENESS TO DRUGS | THE GENERAL HOSPITAL CORPORATION (US) | 2006-10-12 | — | — | WO | disclosed |
| US-7105562-B2 | Geometrically restricted 3-cyclopentylidene-1,3-dihydroindol-2-ones as potent protein tyrosine kinase inhibitors | SUGEN, INC. (US) | 2006-09-12 | — | — | US | disclosed |
| US-20050038066-A1 | Geometrically restricted 3-cyclopentylidene-1,3-dihydroindol-2-ones as potent protein tyrosine kinase inhibitors | SUGEN, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038066-A1 | Geometrically restricted 3-cyclopentylidene-1,3-dihydroindol-2-ones as potent protein tyrosine kinase inhibitors | CKS2, ABL1, ERBB2 | LRRK2 185/4885MAOA 1562/4885MAOB 1178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.